Navigation Links
NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
Date:3/18/2013

o of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's products are based on the cyclophilin inhibitor cyclosporine and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is soon expected to enter a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (http://www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts

NeuroVive Pharmaceutical: Mikael Bronnegard
Email: info@neurovive.com
Phone No: +46(0)70-299-62-64

Citigate Dewe Rogerson: Nina Enegren / David Dible
'/>"/>

SOURCE NeuroVive Pharmaceutical AB
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
2. PCI Appoints John Davis, PE, to Board
3. California Healthcare Institute Appoints Vice President-State Government Affairs
4. Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
5. Quadrant Engineering Plastic Products Appoints a New England Territorial Manager and Production Supervisor
6. Creabilis Appoints Catherine Moukheibir to its Board of Directors
7. Verenium Appoints Holger Liepmann To Its Board Of Directors
8. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
9. Kemwell Appoints Dr. Ninad Deshpanday to Head Global R&D
10. Avantium Appoints Jonathan Wolfson to its Supervisory Board
11. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... (NASDAQ: ANPI , TSX: ANP), a global ... the first New Zealand patient,was treated with Cook ... 2007. A second patient was treated in February,2008. ... stent for peripheral,arterial disease (PAD) and was recently ...
... Krimpets for eight-weeks; 10% of all sales ... to be ... makers of the Tastykake snack line, today announced the re-issue,of Alex,s ... one of the nation,s leading organizations in the,fight against childhood cancer. ...
... SOUTH SAN FRANCISCO, Calif., and SINGAPORE, April 4, ... company focused on the,discovery and development of monoclonal ... Institute (BTI), today announced a,collaboration to advance the ... the terms of the agreement, Raven will license ...
Cached Biology Technology:Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Tasty Baking Company Continues Partnership With Alex's Lemonade Stand Foundation To Fight Childhood Cancer 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
(Date:10/22/2014)...  Leading identity analyst firm Acuity Market Intelligence forecasts ... population will have a chip-based National eID card, including ... Asia , with its vast population, ... than 60% of all National eID cards issued between ... Global National eID Industry Report: 2014 Edition" ...
(Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... of its kind, researchers at Queens College and Mount ... status (SES) and maternal gestational diabetes together may cause ... (ADHD) in six year olds. The data are published ... Pediatrics and Adolescent Medicine , one of the JAMA/Archives ...
... Group, Inc. (Pinksheets: EVRM) would like to issue the ... foremost, I want to thank our supporters; it has ... Evermedia Group, advancing the interests of wholly owned subsidiaries: ... have been fortunate to work with many outstanding professionals ...
... Chimpanzees, orangutans, gorillas and bonobos make more sophisticated decisions ... success, based on what they know and the likelihood to ... Daniel Haun, published on December 21 in the online journal ... human decision-making as well. The authors of the ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2The Evermedia Group 2011 Year in Review 2The Evermedia Group 2011 Year in Review 3The Evermedia Group 2011 Year in Review 4
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
Biology Products: